Molecular Specificity of 5-androstenediol As a Systemic Radioprotectant in Mice
Overview
Pharmacology
Toxicology
Authors
Affiliations
We compared in vivo radioprotective efficacy of 5-androstenediol (5-AED) to that of ten other steroids: 17alpha-androstenediol, dehydroepiandrosterone, 5-androstenetriol (AET), 4-androstenedione (AND), testosterone, estradiol, fluasterone, 16alpha-bromoepiandrosterone, 16alpha-fluoro-androst-5-en-17alpha-ol (alpha-fluorohydrin, AFH), and 16alpha-fluoro-androst-5-en-17beta-ol (beta-fluorohydrin). Steroids were administered 24 or 48 hr before, or 1 hr after, whole-body gamma-irradiation. Two days after irradiation at 3 Gy, blood elements were counted. In addition, after irradiation at 9-12.5 Gy, survival was recorded for 30 days. The results showed radioprotective efficacy was specific for 5-AED. One other steroid, AFH, demonstrated appreciable survival effects but was less efficacious than 5-AED. AND and AET produced slight enhancement of survival in some experiments. This is the first demonstration that the prophylactic window for survival enhancement by 1 subcutaneous (s.c.) injection of 5-AED is as long as 48 hr in mice. Moreover, the results indicate that 1 s.c. injection of 5-AED 1 hr after irradiation is much less effective than 1 injection 24-48 hr before irradiation. Comparing the molecular features of steroids with radioprotective efficacy leads to the following conclusions: 1) these effects are due to interaction with specific receptors, since s.c. injection of extremely similar molecules with the same physicochemical properties as 5-AED were not radioprotective; 2) the 17-hydroxyl group is essential; 3) this group must be in the beta configuration in the absence of nearby side groups; 4) a halogen atom at 16 changes the 17-hydroxyl specificity to alpha; 5) the 3beta-hydroxyl group is not essential; 6) addition of a 7beta-hydroxyl group is deleterious; and 7) the effects are not due to activation of sex steroid receptors.
Fedotcheva T, Uspenskaya M, Ulchenko D, Shimanovsky N Pharmaceuticals (Basel). 2024; 17(9).
PMID: 39338348 PMC: 11435263. DOI: 10.3390/ph17091186.
Singh V, Gupta D, Arora R Discoveries (Craiova). 2020; 3(1):e35.
PMID: 32309561 PMC: 7159829. DOI: 10.15190/d.2015.27.
Pharmacology of natural radioprotectors.
Mun G, Kim S, Choi E, Kim C, Lee Y Arch Pharm Res. 2018; 41(11):1033-1050.
PMID: 30361949 PMC: 6224001. DOI: 10.1007/s12272-018-1083-6.
Hofer M, Hoferova Z, Falk M Int J Mol Sci. 2017; 18(7).
PMID: 28657605 PMC: 5535878. DOI: 10.3390/ijms18071385.
Singh V, Romaine P, Seed T Health Phys. 2015; 108(6):607-30.
PMID: 25905522 PMC: 4418776. DOI: 10.1097/HP.0000000000000279.